$KPTI
Karyopharm Therapeutics Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022007564 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $47.67M $23.26M
YoY Change 104.94% 28.24%
Cost Of Revenue $1.426M $930.0K
YoY Change 53.33% 13.41%
Gross Profit $46.24M $22.33M
YoY Change 107.09% 28.93%
Gross Profit Margin 97.01% 96.0%
Selling, General & Admin $38.77M $37.65M
YoY Change 2.97% 22.73%
% of Gross Profit 83.83% 168.61%
Research & Development $42.06M $37.05M
YoY Change 13.53% 8.98%
% of Gross Profit 90.96% 165.92%
Depreciation & Amortization $177.0K $235.0K
YoY Change -24.68% -2.89%
% of Gross Profit 0.38% 1.05%
Operating Expenses $82.26M $75.63M
YoY Change 8.76% 15.48%
Operating Profit -$34.59M -$52.37M
YoY Change -33.96% 10.59%
Interest Expense $6.684M $5.095M
YoY Change 31.19% -21.72%
% of Operating Profit
Other Income/Expense, Net -$6.683M -$4.892M
YoY Change 36.61% -11.2%
Pretax Income -$41.27M -$57.27M
YoY Change -27.93% 8.32%
Income Tax $130.0K $149.0K
% Of Pretax Income
Net Earnings -$41.40M -$57.41M
YoY Change -27.89% 8.47%
Net Earnings / Revenue -86.84% -246.84%
Basic Earnings Per Share -$0.53
Diluted Earnings Per Share -$533.7K -$770.4K
COMMON SHARES
Basic Shares Outstanding 79.16M
Diluted Shares Outstanding 77.57M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $205.3M $224.4M
YoY Change -8.49% -36.28%
Cash & Equivalents $153.3M $88.47M
Short-Term Investments $52.06M $135.9M
Other Short-Term Assets $29.14M $10.20M
YoY Change 185.64% 18.6%
Inventory $3.874M $3.114M
Prepaid Expenses $12.21M
Receivables $24.99M $17.80M
Other Receivables $0.00 $0.00
Total Short-Term Assets $276.5M $255.5M
YoY Change 8.23% -31.11%
LONG-TERM ASSETS
Property, Plant & Equipment $1.544M $1.984M
YoY Change -22.18% -84.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $7.700M
YoY Change -75.48%
Other Assets $8.438M $700.0K
YoY Change 1105.43% 0.0%
Total Long-Term Assets $17.50M $19.40M
YoY Change -9.78% -57.08%
TOTAL ASSETS
Total Short-Term Assets $276.5M $255.5M
Total Long-Term Assets $17.50M $19.40M
Total Assets $294.0M $274.9M
YoY Change 6.96% -33.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.440M $3.040M
YoY Change 13.16% 78.82%
Accrued Expenses $58.37M $55.61M
YoY Change 4.96% 22.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $66.34M $62.01M
YoY Change 6.98% 24.76%
LONG-TERM LIABILITIES
Long-Term Debt $302.5M $241.8M
YoY Change 25.1% 30.42%
Other Long-Term Liabilities $8.286M $10.70M
YoY Change -22.56% -28.19%
Total Long-Term Liabilities $310.8M $252.5M
YoY Change 23.08% 26.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $66.34M $62.01M
Total Long-Term Liabilities $310.8M $252.5M
Total Liabilities $377.1M $314.5M
YoY Change 19.89% 25.82%
SHAREHOLDERS EQUITY
Retained Earnings -$1.220B -$1.112B
YoY Change 9.72%
Common Stock $1.137B $1.072B
YoY Change 6.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$83.08M -$39.64M
YoY Change
Total Liabilities & Shareholders Equity $294.0M $274.9M
YoY Change 6.96% -33.93%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$41.40M -$57.41M
YoY Change -27.89% 8.47%
Depreciation, Depletion And Amortization $177.0K $235.0K
YoY Change -24.68% -2.89%
Cash From Operating Activities -$59.20M -$52.89M
YoY Change 11.93% 17.5%
INVESTING ACTIVITIES
Capital Expenditures $79.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$13.96M $43.19M
YoY Change -132.31% -192.94%
Cash From Investing Activities -$14.04M $43.19M
YoY Change -132.5% -192.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.78M 10.68M
YoY Change 188.34% -93.52%
NET CHANGE
Cash From Operating Activities -59.20M -52.89M
Cash From Investing Activities -14.04M 43.19M
Cash From Financing Activities 30.78M 10.68M
Net Change In Cash -42.54M 883.0K
YoY Change -4917.55% -98.79%
FREE CASH FLOW
Cash From Operating Activities -$59.20M -$52.89M
Capital Expenditures $79.00K $0.00
Free Cash Flow -$59.28M -$52.89M
YoY Change 12.08% 17.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36167
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Karyopharm Therapeutics Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79418349
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153256000
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
636000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
637000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190459000
CY2022Q1 us-gaap Assets
Assets
294033000
CY2021Q4 us-gaap Assets
Assets
305305000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3440000
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
658-0600
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
KPTI
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
52055000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38156000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
24992000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
22497000
CY2022Q1 us-gaap Inventory Net
InventoryNet
3874000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4106000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12207000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12511000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
29135000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1528000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1014000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6349000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
276533000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
275606000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1544000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1642000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7518000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7915000
CY2022Q1 us-gaap Other Assets
OtherAssets
7802000
CY2021Q4 us-gaap Other Assets
OtherAssets
19505000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1603000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58371000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69121000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2463000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2316000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2063000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
678000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
66337000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
73718000
CY2022Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
169491000
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
169293000
CY2022Q1 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132998000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8286000
CY2021Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132998000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8969000
CY2022Q1 us-gaap Liabilities
Liabilities
377112000
CY2021Q4 us-gaap Liabilities
Liabilities
384978000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79419000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79419000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75746000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75746000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1136873000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1098776000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
87000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
191000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1220047000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1178648000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-83079000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294033000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305305000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47670000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23260000
CY2022Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1426000
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
933000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42062000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37050000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38768000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37650000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
82256000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
75633000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34586000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-52373000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
264000
CY2022Q1 us-gaap Interest Expense
InterestExpense
6684000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6683000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4892000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41269000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57265000
CY2021Q1 us-gaap Interest Expense
InterestExpense
5095000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-73000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
130000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
149000
CY2021Q1 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-343000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-11703000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-41399000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-57414000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77570000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74517000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-41399000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-57414000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-90000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-85000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41503000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57631000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-41399000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-57414000
CY2022Q1 us-gaap Depreciation
Depreciation
177000
CY2021Q1 us-gaap Depreciation
Depreciation
235000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-45000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-664000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
198000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
191000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7336000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7359000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
2000
CY2021Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
14000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
82000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2495000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4962000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-232000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
552000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27303000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
89000
CY2022Q1 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-397000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1837000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1410000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9387000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3432000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-297000
CY2022Q1 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-536000
CY2021Q1 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-456000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59197000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52888000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
CY2021Q1 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
9903000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1467000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
773000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30783000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21584000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
68950000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
35540000
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
25764000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14035000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43186000
CY2022Q1 kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
29316000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10676000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-90000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-91000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42539000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
883000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89121000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154906000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90004000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153256000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88471000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1014000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
815000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
636000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
718000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154906000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90004000
CY2022Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
22000
CY2021Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2022Q1 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
841000
CY2021Q1 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
815000
CY2022Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
15784000
CY2021Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
2457000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1467000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7336000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29294000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-90000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-41399000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-83079000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
50546000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
773000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7359000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-57414000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-39640000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9903000
CY2021Q1 kpti Cumulative Effect Adjustment For Adoption Of New Accounting Guidance
CumulativeEffectAdjustmentForAdoptionOfNewAccountingGuidance
-50590000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-85000
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
2563000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1797000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
926000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1895000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
385000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
414000
CY2022Q1 us-gaap Inventory Net
InventoryNet
3874000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4106000
CY2022Q1 kpti Revenue Recognition Potential Future Milestone Payments
RevenueRecognitionPotentialFutureMilestonePayments
8600000
CY2022Q1 kpti Reimbursement Of Development Related Expenses
ReimbursementOfDevelopmentRelatedExpenses
7100000
CY2022Q1 kpti Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
8600000
CY2021Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3080000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
150243000
CY2022Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3080000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
95101000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
52071000
CY2022Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
5000
CY2022Q1 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
21000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
52055000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38161000
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
9000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38156000
CY2022Q1 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2022Q1 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
16
CY2021Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
37
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
42056000
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
21000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
42056000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
21000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
26650000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
9000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
26650000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
9000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7336000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7359000
CY2022Q1 kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five business day period immediately after any five consecutive trading day period
CY2022Q1 kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
CY2022Q1 kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98
CY2022Q1 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
CY2022Q1 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3100000

Files In Submission

Name View Source Status
0000950170-22-007564-index-headers.html Edgar Link pending
0000950170-22-007564-index.html Edgar Link pending
0000950170-22-007564.txt Edgar Link pending
0000950170-22-007564-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img180826833_0.jpg Edgar Link pending
kpti-20220331.htm Edgar Link pending
kpti-20220331.xsd Edgar Link pending
kpti-20220331_cal.xml Edgar Link unprocessable
kpti-20220331_def.xml Edgar Link unprocessable
kpti-20220331_htm.xml Edgar Link completed
kpti-20220331_lab.xml Edgar Link unprocessable
kpti-20220331_pre.xml Edgar Link unprocessable
kpti-ex10_3.htm Edgar Link pending
kpti-ex10_4.htm Edgar Link pending
kpti-ex10_5.htm Edgar Link pending
kpti-ex10_8.htm Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
kpti-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending